Enable JavaScript to visit this website.
Skip to main content

User menu

  • Log in
  • Register

Main menu

  • Pfizer Products
  • Therapy Areas

Search form

Pfizer Home
  • MAGNEX®

Clinical Information

  • About MAGNEX®
  • MAGNEX® Indications
  • IAI
  • UTI
  • RTI
  • Febrile Neutropenia
  • Clinical Efficacy of MAGNEX®
  • Safety Profile
  • Guidelines and Recommendations
  • Dosing
  • Summary of Prescribing Information

Support & Services

  • Clinical Update (5)
  • MAGNEX® Summary of Product Information
magnexr--indications-banner
Indication: Monotherapy– Sulbactam/Cefoperazone is indicated for the treatment of the following infections when caused by susceptible organisms: RTIs, UTIs (upper and lower), IAIs, septicaemia, meningitis, skin and soft tissue infections, bone and joint infections, endometritis and other infections in the genital tract. MAGNEX® FORTE is indicated for a specific subset of patients (patients with immunocompromised febrile neutropenic cancer, patients who have undergone a bone marrow transplant).1

Clinical Information List

About MAGNEX®

MAGNEX® Indications

IAI

UTI

RTI

Febrile Neutropenia

Clinical Efficacy of MAGNEX®

Safety Profile

Guidelines and Recommendations

Dosing

Summary of Prescribing Information

Pfizer Home
  • MAGNEX®

Clinical Information

  • About MAGNEX®
  • MAGNEX® Indications
  • IAI
  • UTI
  • RTI
  • Febrile Neutropenia
  • Clinical Efficacy of MAGNEX®
  • Safety Profile
  • Guidelines and Recommendations
  • Dosing
  • Summary of Prescribing Information

Support & Services

  • Clinical Update (5)
  • MAGNEX® Summary of Product Information
Find out more
Find out more
Find out more

Footer menu

  • Pfizer.com
  • Privacy Policy
  • Terms of Use
  • Send us a Medical Question
  • Request for a Publications Update

Copyright footer block

Copyright © 2021 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
•All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
•While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein

These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.

For the use only of Registered Medical Practitioners* or a Hospital or a Laboratory.

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

If you select ‘No’, you will be redirected to Pfizerindia.com.

For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.

Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051.
PP-UPA-IND-0089. 11/2/2021.

YesNo